Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Receivables (2017 - 2025)

Assembly Biosciences (ASMB) has 9 years of Receivables data on record, last reported at $912000.0 in Q3 2025.

  • For Q3 2025, Receivables changed N/A year-over-year to $912000.0; the TTM value through Sep 2025 reached $912000.0, changed N/A, while the annual FY2023 figure was $43000.0, 95.44% down from the prior year.
  • Receivables reached $912000.0 in Q3 2025 per ASMB's latest filing, up from $43000.0 in the prior quarter.
  • Across five years, Receivables topped out at $1.2 million in Q3 2022 and bottomed at $43000.0 in Q4 2023.
  • Average Receivables over 5 years is $530692.3, with a median of $523000.0 recorded in 2022.
  • Peak YoY movement for Receivables: skyrocketed 180.95% in 2022, then crashed 95.44% in 2023.
  • A 5-year view of Receivables shows it stood at $336000.0 in 2021, then soared by 180.95% to $944000.0 in 2022, then plummeted by 95.44% to $43000.0 in 2023, then changed by 0.0% to $43000.0 in 2024, then skyrocketed by 2020.93% to $912000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $912000.0 in Q3 2025, $43000.0 in Q1 2024, and $43000.0 in Q4 2023.